Eli Lilly and Company
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
Dominant GLP-1 franchise with patent protection into the late 2030s, reinforced by a deep clinical pipeline and manufacturing scale advantages.
Eli Lilly's moat is anchored in scientific superiority and regulatory exclusivity that cannot be replicated quickly:
- Tirzepatide Efficacy Superiority: Mounjaro and Zepbound (tirzepatide) consistently outperform competing GLP-1 drugs in head-to-head efficacy data, with superior weight loss outcomes. This clinical evidence edge drives prescriber preference and formulary positioning that competitors must overcome with their own Phase 3 trial data — a multi-year barrier.
- Patent Wall Into the Late 2030s: Lilly's CEO has confirmed tirzepatide compound patent protection extends 'into the back half of the 2030s' in major markets, contrasting sharply with Novo Nordisk's semaglutide facing patent expiry in select markets today. This 10+ year runway allows Lilly to compound its GLP-1 franchise revenues without near-term generic erosion.
- Manufacturing Moat at Scale: Peptide manufacturing is extraordinarily complex; Lilly has invested billions into new manufacturing capacity globally. The expertise required to manufacture GLP-1 drugs at commercial scale — including sterile fill-finish and cold-chain logistics — represents a structural barrier that takes years for competitors to build.
Moat Verdict
Lilly's core moat — patent-protected biologics with regulatory approval — is structurally immune to AI disruption, and AI drug discovery tools actually accelerate Lilly's pipeline advantage by compressing early-stage discovery timelines. The company is a net beneficiary of AI adoption, using it to identify novel targets and optimize clinical trials faster than underfunded competitors.
72.0 resilient · 74.2 vulnerable · 80/20 = 72.4 · = 72
Open a moat to read its note.
physicians prescribe drugs based on clinical evidence and patient outcomes, not UI familiarity; interface learning costs do not apply to pharmaceuticals.
Lilly's GLP-1 peptide synthesis, formulation IP, and cold-chain manufacturing know-how represent complex proprietary processes that competitors cannot decode from reverse engineering alone.
Lilly's competitive moat does not rely on controlling access to a public data source; not applicable to the pharmaceutical business model.
World-class endocrinologists, peptide chemists, and regulatory affairs specialists are scarce globally; Lilly's 140-year reputation and compensation attract the best pharma talent disproportionately.
pharmaceutical drugs are not sold in software-style bundles; individual drug approvals and prescriptions are the unit of sale.
Lilly holds large tirzepatide trial and real-world outcomes datasets that support label expansions, but Novo and the next incretin entrants run their own trials, and the data's value is the approval it supports, rated under regulatoryLockIn. Re-rated from strong to intact in the proof-point pass.
Mounjaro, Zepbound and now Foundayo (FDA-approved April 1, 2026) each carry FDA approvals, EU and global clearances, GMP manufacturing certification and payer formulary placement. Those take years to replicate, but every large GLP-1 maker holds the same kind, Novo Nordisk first among them, so they are table stakes and rate intact, the call Novo's pillar already carries. Product-specific patent exclusivity on tirzepatide is the open question of how patents score, not counted here. Re-rated from strong to intact.
Growing physician experience with tirzepatide creates a prescribing flywheel — more patient success stories build prescriber confidence and peer recommendations. Foundayo's April 2026 launch extends this network into the oral GLP-1 segment, deepening the flywheel across both injectable and pill modalities.
Mounjaro and Zepbound are embedded in major pharmacy benefit formularies, employer health plans, and Medicare Part D — removing them faces enormous patient, physician, and political resistance.
Lilly is a drug manufacturer, not a system-of-record platform; this moat type does not apply to the pharmaceutical industry.
The largest incretin manufacturing build-out in the industry — more than $50B committed to US manufacturing since 2020 — covering API, fill-finish and device capacity at a scale that let Lilly supply demand and cut price where Novo was supply-constrained.
Prescribing follows efficacy, label and formulary position, not the manufacturer's name; no brand premium independent of the approvals.
Combined average of Moat (AI Resilience), Growth, and Valuation scores.
Moat Score
Dominant GLP-1 franchise with patent protection into the late 2030s, reinforced by a deep clinical pipeline and manufacturing scale advantages.
Growth Score
Q2 2026 (Aug 5): Revenue rose 48% YoY to $23.0B, driven by 60% volume growth partly offset by a 13% realised-price decline. Non-GAAP EPS was $8.38 and key products contributed $15.7B, led by Mounjaro at $9.94B (+91% YoY) and Zepbound at $4.93B (+46%). Management raised FY2026 revenue guidance to $85-87B from $82-85B and raised the underlying non-GAAP EPS outlook by $2.78 at the midpoint, though acquired IPR&D charges left reported non-GAAP EPS guidance at $35.50-$36.50. Q2 was the first report including Foundayo after its April approval, while retatrutide remains the next major injectable catalyst with planned 2027 submission work and additional 2026 readouts.
Valuation Score
At $1,220.28, Lilly trades about 44% above the rebuilt bear case ($850) and roughly 13% below the new base case ($1,400). The old $1,200 base case is stale after Q2 revenue beat by a wide margin and FY2026 sales guidance moved to $85-87B. The stock is still expensive at roughly 34x the updated 2026 non-GAAP EPS guide, but the Q2 GLP-1 run rate and raised revenue/margin outlook justify a higher 12-24 month fair value.
The GLP-1 Fortress
Eli Lilly's moat is anchored in scientific superiority and regulatory exclusivity that cannot be replicated quickly:
- Tirzepatide Efficacy Superiority: Mounjaro and Zepbound (tirzepatide) consistently outperform competing GLP-1 drugs in head-to-head efficacy data, with superior weight loss outcomes. This clinical evidence edge drives prescriber preference and formulary positioning that competitors must overcome with their own Phase 3 trial data — a multi-year barrier.
- Patent Wall Into the Late 2030s: Lilly's CEO has confirmed tirzepatide compound patent protection extends 'into the back half of the 2030s' in major markets, contrasting sharply with Novo Nordisk's semaglutide facing patent expiry in select markets today. This 10+ year runway allows Lilly to compound its GLP-1 franchise revenues without near-term generic erosion.
- Manufacturing Moat at Scale: Peptide manufacturing is extraordinarily complex; Lilly has invested billions into new manufacturing capacity globally. The expertise required to manufacture GLP-1 drugs at commercial scale — including sterile fill-finish and cold-chain logistics — represents a structural barrier that takes years for competitors to build.
Moat Verdict
Lilly's core moat — patent-protected biologics with regulatory approval — is structurally immune to AI disruption, and AI drug discovery tools actually accelerate Lilly's pipeline advantage by compressing early-stage discovery timelines. The company is a net beneficiary of AI adoption, using it to identify novel targets and optimize clinical trials faster than underfunded competitors.
72.0 resilient · 74.2 vulnerable · 80/20 = 72.4 · = 72
Open a moat to read its note.
physicians prescribe drugs based on clinical evidence and patient outcomes, not UI familiarity; interface learning costs do not apply to pharmaceuticals.
Lilly's GLP-1 peptide synthesis, formulation IP, and cold-chain manufacturing know-how represent complex proprietary processes that competitors cannot decode from reverse engineering alone.
Lilly's competitive moat does not rely on controlling access to a public data source; not applicable to the pharmaceutical business model.
World-class endocrinologists, peptide chemists, and regulatory affairs specialists are scarce globally; Lilly's 140-year reputation and compensation attract the best pharma talent disproportionately.
pharmaceutical drugs are not sold in software-style bundles; individual drug approvals and prescriptions are the unit of sale.
Lilly holds large tirzepatide trial and real-world outcomes datasets that support label expansions, but Novo and the next incretin entrants run their own trials, and the data's value is the approval it supports, rated under regulatoryLockIn. Re-rated from strong to intact in the proof-point pass.
Mounjaro, Zepbound and now Foundayo (FDA-approved April 1, 2026) each carry FDA approvals, EU and global clearances, GMP manufacturing certification and payer formulary placement. Those take years to replicate, but every large GLP-1 maker holds the same kind, Novo Nordisk first among them, so they are table stakes and rate intact, the call Novo's pillar already carries. Product-specific patent exclusivity on tirzepatide is the open question of how patents score, not counted here. Re-rated from strong to intact.
Growing physician experience with tirzepatide creates a prescribing flywheel — more patient success stories build prescriber confidence and peer recommendations. Foundayo's April 2026 launch extends this network into the oral GLP-1 segment, deepening the flywheel across both injectable and pill modalities.
Mounjaro and Zepbound are embedded in major pharmacy benefit formularies, employer health plans, and Medicare Part D — removing them faces enormous patient, physician, and political resistance.
Lilly is a drug manufacturer, not a system-of-record platform; this moat type does not apply to the pharmaceutical industry.
The largest incretin manufacturing build-out in the industry — more than $50B committed to US manufacturing since 2020 — covering API, fill-finish and device capacity at a scale that let Lilly supply demand and cut price where Novo was supply-constrained.
Prescribing follows efficacy, label and formulary position, not the manufacturer's name; no brand premium independent of the approvals.
Growth Analysis
Growth Drivers
Key Risk
If realised GLP-1 prices keep falling faster than volume growth, while oral GLP-1 competition narrows Foundayo's advantage or retatrutide readouts fall short of best-in-class expectations, 2027-2028 EPS estimates could reset lower despite strong current demand.
Score Derivation
82.3 base + 4 margin − 5 risk = 81
Base 82.3 (15-22% CAGR, midpoint 18.5%, compounded off the ~$86B FY2026 base) + 0 trajectory (Mounjaro stable, Zepbound decelerating, oral/retatrutide accelerating) + 4 expanding margins - 5 moderate pricing/concentration risk = 81
Price Scenarios (12–24 Months)
Valuation Multiples
| Normalized P/E | ~41× |
| Forward P/E (NTM) | ~34× |
| PEG Ratio | ~0.9× |
| Price / Sales (NTM) | ~13× |
| Price / FCF | ~35-40× |
Lilly is no longer a bargain on absolute multiples, but the valuation is still anchored by measured growth rather than hope: Q2 revenue grew 48%, key products reached $15.7B, and revenue guidance rose again. The key risk is mix and price: Mounjaro and Zepbound volumes are surging, but realised prices are falling. Upside to the bull case requires retatrutide and Foundayo to broaden the franchise before pricing pressure slows the injectable GLP-1 curve.
Approximate figures as of August 2026.
Where We Are vs Targets
Loading live price…
Foundayo adoption disappoints as Wegovy pill leads on scripts, pricing pressure erodes net revenue, and a retatrutide late Phase 3 setback removes the next-gen premium.
- U.S. GLP-1 realised prices continue falling, offsetting a larger share of Mounjaro and Zepbound volume growth than expected
- Foundayo adoption trails oral competitors and fails to expand the market beyond injection-averse patients
- Retatrutide late-stage data lands closer to existing injectable efficacy, removing the best-in-class next-gen premium
Mounjaro and Zepbound sustain volume-led growth, Foundayo broadens the oral GLP-1 funnel, and FY2026 revenue closes near the high end of the raised guide.
- FY2026 revenue lands in the $85-87B range with non-GAAP performance margin at 49.0-50.5%
- Mounjaro and Zepbound maintain strong volume growth even as realised prices decline, keeping combined quarterly sales above $15B entering 2027
- Foundayo and retatrutide progress keep Lilly positioned as the broadest oral/injectable incretin franchise
Retatrutide becomes the best-in-class weight-loss drug confirmed by Phase 3 data, Foundayo accelerates to mainstream oral adoption, and Kisunla reaches blockbuster scale.
- Retatrutide Phase 3 breadth confirms best-in-class efficacy and sets up a 2027 filing with materially higher peak-sales expectations
- Foundayo penetrates a large share of oral obesity prescriptions and expands the treated population beyond injection users
- Non-GLP-1 key products in immunology, oncology and neuroscience keep growing fast enough to reduce franchise concentration